92 related articles for article (PubMed ID: 2524766)
1. [Central core disease associated with malignant hyperthermia sensitivity].
Krivosic-Horber R; Krivosic I
Presse Med; 1989 Apr; 18(16):828-31. PubMed ID: 2524766
[TBL] [Abstract][Full Text] [Related]
2. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
[TBL] [Abstract][Full Text] [Related]
3. [Incidence of disposition for malignant hyperthermia in patients with neuromuscular diseases].
Wappler F; Scholz J; von Richthofen V; Fiege M; Köchling A; Matschke J; Winkler G; Schulte am Esch J
Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Jun; 33(6):373-80. PubMed ID: 9689395
[TBL] [Abstract][Full Text] [Related]
4. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis.
O'Flynn RP; Shutack JG; Rosenberg H; Fletcher JE
Anesthesiology; 1994 Jun; 80(6):1228-33. PubMed ID: 8010468
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis of susceptibility to malignant hyperthermia in children].
Krivosic-Horber R; Adnet P; Krivosic I; Reyford H
Arch Fr Pediatr; 1990; 47(6):421-4. PubMed ID: 2403268
[TBL] [Abstract][Full Text] [Related]
6. Segregation of malignant hyperthermia, central core disease and chromosome 19 markers.
Curran JL; Hall WJ; Halsall PJ; Hopkins PM; Iles DE; Markham AF; McCall SH; Robinson RL; West SP; Bridges LR; Ellis FR
Br J Anaesth; 1999 Aug; 83(2):217-22. PubMed ID: 10618932
[TBL] [Abstract][Full Text] [Related]
7. [Lack of sensitivity to per-anesthetic malignant hyperthermia in 32 patients who developed neuroleptic malignant syndrome].
Bello N; Adnet P; Saulnier F; Lestavel P; Adnet-Bonte C; Reyford H; Etchrivi T; Tavernier B; Krivosic-Horber R
Ann Fr Anesth Reanim; 1994; 13(5):663-8. PubMed ID: 7733515
[TBL] [Abstract][Full Text] [Related]
8. Malignant hyperthermia susceptibility without central core disease (CCD) in a family where CCD is diagnosed.
Islander G; Henriksson KG; Ranklev-Twetman E
Neuromuscul Disord; 1995 Mar; 5(2):125-7. PubMed ID: 7767091
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
Mortier W; Breucking E
Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
[TBL] [Abstract][Full Text] [Related]
10. Malignant hyperthermia and central core disease in a child with congenital dislocating hips.
Eng GD; Epstein BS; Engel WK; McKay DW; McKay R
Arch Neurol; 1978 Apr; 35(4):189-97. PubMed ID: 637752
[TBL] [Abstract][Full Text] [Related]
11. Screening test for malignant hyperthermia in patients with persistent hyperCKemia: a pilot study.
Johannsen S; Berberich C; Metterlein T; Roth C; Reiners K; Roewer N; Schuster F
Muscle Nerve; 2013 May; 47(5):677-81. PubMed ID: 23400941
[TBL] [Abstract][Full Text] [Related]
12. Malignant hyperthermia.
Rosenberg H; Davis M; James D; Pollock N; Stowell K
Orphanet J Rare Dis; 2007 Apr; 2():21. PubMed ID: 17456235
[TBL] [Abstract][Full Text] [Related]
13. Halothane-caffeine contracture testing in neuromuscular diseases.
Heiman-Patterson TD; Rosenberg H; Fletcher JE; Tahmoush AJ
Muscle Nerve; 1988 May; 11(5):453-7. PubMed ID: 3374516
[TBL] [Abstract][Full Text] [Related]
14. An association between certain congenital abnormalities and the malignant hyperthermia trait.
Gericke GS; Isaacs H
S Afr Med J; 1990 Jun; 77(11):570-4. PubMed ID: 2345883
[TBL] [Abstract][Full Text] [Related]
15. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
Ording H; Bendixen D
Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
[TBL] [Abstract][Full Text] [Related]
16. Neuromyopathy in malignant hyperthermia.
Rivera VM; Patten BM
J Clin Psychiatry; 1978 Jan; 39(1):67-71. PubMed ID: 580262
[TBL] [Abstract][Full Text] [Related]
17. Malignant hyperthermia and central core disease causative mutations in Swedish patients.
Broman M; Islander G; Müller CR; Ranklev-Twetman E
Acta Anaesthesiol Scand; 2007 Jan; 51(1):50-3. PubMed ID: 17081152
[TBL] [Abstract][Full Text] [Related]
18. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
[TBL] [Abstract][Full Text] [Related]
19. Serum creatine kinase level as a screening test for susceptibility to malignant hyperthermia.
Paasuke RT; Brownell AK
JAMA; 1986 Feb; 255(6):769-71. PubMed ID: 3944979
[TBL] [Abstract][Full Text] [Related]
20. Masseter muscle rigidity and malignant hyperthermia susceptibility.
Rosenberg H; Fletcher JE
Anesth Analg; 1986 Feb; 65(2):161-4. PubMed ID: 3942303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
